Positive Wound Autograft Data Presented

Reapplix ApS (Birkerød, Denmark) presented positive outcome data of an independent randomized controlled trial (RCT) of its LeucoPatch wound healing platform (also marketed as 3CPatch in the United States) at the American Diabetes Association 78th Scientific Sessions (Orlando, FL). This observer-blinded RCT demonstrated that patients treated with an application of the platform in addition to standard of care had a 58% increased chance of healing. 

The platform is a novel technology that uses cells and growth factors from a sample of a patient’s blood to produce a “patch” at the point of care. This patch, without reagents or additives, is then applied topically for the management of exuding cutaneous wounds.

Visit www.reapplix.com for more information.